ELTP (Elite Pharmaceuticals) 6-Month Price Index: 0.70 (As of Aug. 30, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ELTP Elite Pharmaceuticals Inc ELTP
55 GF Score
Price $0.29
GF Value $0.51
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Elite Pharmaceuticals 6-Month Price Index?

Elite Pharmaceuticals ELTP +0.30% 55 6-Month Price Index is 0.70 as of Aug. 30, 2026. GuruFocus rates ELTP with a GF Score™ of 55/100 and a GF Value™ of $0.51 (Significantly Undervalued). The stock has 2 warning signs investors should review.

6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. It’s calculated by current share price divided by share price 6-months ago. As of today (2026-08-30), Elite Pharmaceuticals's 6-Month Price Index is 0.70.

Elite Pharmaceuticals  (OTCPK:ELTP) 6-Month Price Index Explanation

Price Index (PI) also called momentum. Strategies involving Price Index are also known as momentum strategies as they allow investors to profit from a company’s stock price. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago.

The investment strategy for momentum investors is to buy winners and sell losers. That is, buy stocks that performed well and sell stocks that performed poorly in the past.

Elite Pharmaceuticals 6-Month Price Index Related Terms

ELTP vs EOLS, EBS, AQST: 6-Month Price Index Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Elite Pharmaceuticals's 6-Month Price Index, along with its competitors' market caps and 6-Month Price Index data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ELTP
55GF Score
Elite Pharmaceuticals Inc ELTP
6-Month Price Index is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Elite Pharmaceuticals  (OTCPK:ELTP) 6-Month Price Index Calculation

6-Month Price Index is calculated as following:

6-Month Price Index=Current Share Price / Share Price 6-Months Ago

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 6-Month Price Index →
What does a 6-Month Price Index of 0.70 mean?
Elite Pharmaceuticals (ELTP) has a 6-Month Price Index of 0.70 as of Aug. 30, 2026. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. View historical data on Elite Pharmaceuticals and its competitors.
Is Elite Pharmaceuticals' 6-Month Price Index too high?
Elite Pharmaceuticals' current 6-Month Price Index is 0.70. Overall, Elite Pharmaceuticals has a GF Score™ of 55/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Elite Pharmaceuticals' 6-Month Price Index compare to EOLS and EBS?
Elite Pharmaceuticals' 6-Month Price Index of 0.70 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 6-Month Price Index for a Drug Manufacturers company?
A good 6-Month Price Index depends on the Drug Manufacturers industry context. However, 6-Month Price Index should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 6-Month Price Index mean?
A high 6-Month Price Index can signal that a stock is expensive relative to its fundamentals. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. View historical data on Elite Pharmaceuticals and its competitors. Elite Pharmaceuticals's current 6-Month Price Index is 0.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Elite Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Elite Pharmaceuticals (ELTP) is currently considered Significantly Undervalued. The stock's GF Value™ is $0.51, compared to a current price of $0.29 — trading 43.4% below its estimated fair value. The current 6-Month Price Index is 0.70. Elite Pharmaceuticals' overall GF Score™ is 55/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 6-Month Price Index calculated?
6-Month Price Index is calculated from a company's financial statements. For Elite Pharmaceuticals (ELTP), the current 6-Month Price Index is 0.70 as of Aug. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Elite Pharmaceuticals (ELTP) Overvalued in 2026?

Based on GuruFocus' analysis, Elite Pharmaceuticals stock appears to be undervalued. The current stock price of $0.29 is trading 43.4% below its estimated GF Value™ of $0.51. GuruFocus considers Elite Pharmaceuticals to be Significantly Undervalued.

Key valuation signals for ELTP:

  • 6-Month Price Index: 0.70
  • GF Value™: $0.51 vs. price of $0.29 (43.4% below fair value)
  • GF Score™: 55/100 with 2 warning signs

No single metric tells the full story. See the ELTP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Elite Pharmaceuticals Business Description

Address 165 Ludlow Avenue, Northvale, NJ, USA, 07647
Elite Pharmaceuticals Inc is a pharmaceutical company. It is principally engaged in the development and manufacture of oral, controlled-release products, using proprietary know-how and technology. The company's operating segment includes Abbreviated New Drug Applications (ANDA) and New Drug Applications (NDA). It generates maximum revenue from the ANDA segment. The company focuses on developing pain management products; manufacturing a line of generic pharmaceutical products with approved Abbreviated New Drug Applications; developing additional generic pharmaceutical products; development of other products in its pipeline including the products with its partners; and commercialization of new products.
55GF Score

Get the complete analysis for ELTP

6-Month Price Index is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.29
Price
$0.51
GF Value